TechMARK movers: Oxford Biomedica amends antigen licence

18th Jun 2010 14:46

Gene therapy company Oxford Biomedica has agreed an amendment to its licence with Cancer Research Technology covering the 5T4 antigen used in the Tro-Vax cancer vaccine. The deal covers royalties due to CRT relating to the sanofi-aventis TroVax agreement (signed March 2007 and terminated April 2009). The payment will be staged according to the achievement of milestones. There will be an initial cash payment of £100,000 plus £185,000 worth of shares at 10.25p each. Further payments will be made when commercial and clinical milestones happen. Shares in Consort Medical have recovered yesterday's loss after the drug delivery devices supplier reported its full year figures to April 2010. Consort reported a 6% decrease in underlying profit to £16.9m on slightly lower revenues of £118.6m. The final dividend was unchanged at 12.1p a share. Singer forecasts a small rise in profit to £17m and has set a share price target of 448p. FTSE TechMARK - RisersPuricore (PURI) 8.50p +8.82%Antisoma (ASM) 6.44p +6.10%Kofax (KFX) 260.00p +4.52%Vislink (VLK) 18.25p +4.11%Oxford Instruments (OXIG) 292.00p +3.73%Vectura Group (VEC) 47.00p +3.30%Alterian (ALN) 155.00p +3.16%Consort Medical (CSRT) 368.75p +3.00%Vernalis (VER) 38.00p +2.70%Triad Group (TRD) 23.50p +2.17%FTSE TechMARK - FallersCryptologic Ld (CRP) 185.00p -19.57%Dialight (DIA) 280.00p -6.67%Kewill (KWL) 117.00p -4.49%Psion (PON) 80.00p -4.19%Emblaze (BLZ) 35.00p -2.78%Oxford Biomedica (OXB) 10.00p -2.44%NXT (NTX) 10.50p -2.33%E2V Technologies (E2V) 48.50p -2.02%KCOM Group (KCOM) 49.75p -1.97%BT Group (BT.A) 138.00p -1.15%